Drug Approval | January 31, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The new campus has been designed as an employee-centred experience and ecosystem zone
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated
